ApoB / LDL-C / Lp(a) — Therapeutic Strategy

Your decision view across every lipid-lowering lever. Personalized for your phenotype (ApoB 108, Lp(a) 90 nmol/L, CAC 0).
Built: 27 May 2026 Patient: Bambos Kaisharis (48M) Wild-type: ABCG5/8 ✓ Currently on: Psyllium 5 g/day → uptitrating

TL;DR — Your Recommended Sequence

The single answer

  1. Now → end of Q2 2026: Get psyllium to 5 g BID (morning shake + dinner). This is your baseline nutraceutical lever — established, cheap, safe.
  2. Q3 2026 (your next pharmacological move): Ezetimibe 10 mg/day. Rx, $10/mo generic. Expected: ApoB ~108 → ~91 mg/dL. Re-test labs at 12 weeks.
  3. If ApoB still >80 at 12-week recheck: Add low-dose statin (rosuvastatin 5 mg) OR bempedoic acid 180 mg if statin-hesitant. Target: ApoB <70 mg/dL.
  4. Lp(a) lever (your dominant long-term driver): Wait — Pelacarsen (Ph3 HORIZON, readout ~2027) and Olpasiran (Ph3 OCEAN(a), readout ~2027–2028) are the real Lp(a) solutions. See Lp(a) tracker for current pipeline status.
  5. Skip for now: Plant sterols (competes with ezetimibe on NPC1L1), PCSK9 mAbs (overkill at this phenotype), Inclisiran (reserved for after statin+ezetimibe failure).
  6. Re-CAC in 2029. If trajectory remains zero, validates current approach. If non-zero, escalate.

Your Baseline (Quest, Jan 2026)

ApoB
108
mg/dL · target <80
Above target
LDL-C
~140
mg/dL · target <100
Above target
Lp(a)
90
nmol/L · target <75
Elevated
HDL-C
~55
mg/dL · target >40
On target
CAC
0
Aug 2024 · re-test 2029
Zero burden
HbA1c
5.6
% · target <5.7
Top of normal
The discordant signal: Elevated ApoB + Lp(a) with CAC 0 means atherogenic burden is accumulating in the lipoprotein phase but hasn't yet manifested as calcified plaque. This is the right window to intervene — lower ApoB now, before soft-plaque builds.

What You're Already Doing — and How to Optimize It

Current stack (verified May 2026)
Yerba Prima Psyllium Husk Powder 24 oz fine-ground · pure psyllium, sugar-free, unflavored · delivered 24 May 2026
Current dose: 5 g/day in morning shake (with casein, creatine, cocoa, allulose)
Target: 10 g/day. Question: split or all-AM?
Recommended: 5 g BID — keep AM shake, add 5 g with your largest evening meal.
Evidence basis: Anderson et al. 26-week multicenter RCT validated this exact regimen (5.1 g twice daily) → sustained 6.7% LDL drop over 6 months. Cross-over trial (PMC522822) showed morning vs. evening total-dose timing makes no measurable difference, but splitting matters because bile-acid binding only happens during meals — one 10 g dose only catches one meal's bile acid pool; splitting catches two.
Practical: Stir 5 g into 250+ mL water/juice 15 min before dinner. Drink quickly (it thickens fast). Wait 30 min between psyllium and any meds (it can blunt absorption).
If compliance is the issue: all 10 g in the AM shake is still ~75–80% as effective as split. Don't let perfect be the enemy of done.
Don't exceed 10 g/day routinely — meta-analysis shows no additional LDL benefit above 10 g, but GI side effects (bloating, gas) scale up.
Plant sterols Considered — see deep-dive for products
Status: Pending decision. Recommendation: defer until you've decided on ezetimibe. If you start ezetimibe, drop sterols (compete for the same NPC1L1 transporter — ezetimibe wins).
If you DON'T start ezetimibe and want a nutraceutical layer: NOW Foods Beta-Sitosterol + CardioAid-S + Fish Oil, 4 sg/day = 2 g.

The Therapeutic Hierarchy

Every lipid-lowering lever, sorted by ApoB / LDL-C reduction potency

Approximate effect sizes from monotherapy trials. Color coding: lifestyle/OTC (blue), Rx available now (dark), emerging/clinical-trial (amber), future (teal). Hover or read labels for evidence strength.

Full Comparison Matrix

Lever Type LDL-C Δ ApoB Δ Lp(a) Δ CV outcome data Route / Frequency Cost/mo Status
Mediterranean diet
Sat-fat <7% kcal		 Lifestyle −5 to −15% −3 to −10% ~0 PREDIMED (yes, modest) Daily $0 Foundational
Aerobic exercise
Zone 2, 150+ min/wk		 Lifestyle −5 to −10% −5% ~0 Indirect (CV mortality) Daily/weekly $0 Foundational
Psyllium husk
10 g/day BID		 OTC −7 to −10% −5% ~0 Biomarker only Oral, BID with meals $10 You're on it
Phytosterols
2 g/day		 OTC −8 to −10% −5 to −8% −1 to −2% None (109 RCTs biomarker only) Oral, with meals $20 Available · deep-dive
Ezetimibe
Zetia · NPC1L1 inhibitor		 Rx −18 to −20% −15 to −20% ~0 Yes — IMPROVE-IT 2015 Oral, 1×/day $10 generic Your next step
Statin — low-dose
Rosuva 5 mg / Atorva 10 mg		 Rx −30 to −40% −25 to −35% +10 to +20% Yes — extensive Oral, 1×/day $5–10 generic First-line per guidelines
Statin — high-intensity
Rosuva 20–40 / Atorva 40–80		 Rx −45 to −55% −40 to −50% +10 to +30% Yes — strongest base of any class Oral, 1×/day $5–15 generic Indicated if 2°-prevention
Bempedoic acid
Nexletol · ACL inhibitor		 Rx −17 to −25% −15 to −20% ~0 Yes — CLEAR-Outcomes 2023 Oral, 1×/day $400 branded Statin-alternative
PCSK9 mAb
Repatha / Praluent		 Rx −55 to −65% −50 to −60% −20 to −30% Yes — FOURIER, ODYSSEY SubQ injection q2w $500–650 (insur) Reserved for high-risk
Inclisiran
Leqvio · siRNA PCSK9		 Rx −50% −40 to −45% −20 to −25% Surrogate; CV outcome (ORION-4) due 2026 SubQ q6 months $3,250/dose Available · post-statin/ezet
Pelacarsen
ASO targeting LPA mRNA		 Emerging ~−5% ~−10% −80% Ph3 HORIZON — readout ~2027 SubQ q month TBD Likely FDA 2027–2028
Olpasiran
siRNA against LPA		 Emerging ~−5% ~−10% −94% Ph3 OCEAN(a) — readout 2027–2028 SubQ q12 weeks TBD Likely FDA 2028
Lepodisiran
siRNA against LPA		 Emerging ~−5% ~−10% −94% Ph2/3 SubQ q6 months TBD Following Olpasiran
Muvalaplin
First oral Lp(a) inhibitor		 Emerging ~0 ~−5% −85% Ph2 KRAKEN Oral, 1×/day TBD Oral is the game-changer
Obicetrapib
CETP inhibitor		 Emerging −50% −30 to −35% −40 to −50% Ph3 BROADWAY/BROOKLYN — positive readouts 2025 Oral, 1×/day TBD FDA likely 2026–2027
Verve VERVE-102
Base-editor PCSK9 gene therapy		 Future −55% −50% ~0 Ph1b Heart-2 Single-dose IV — lifetime $$$ TBD ~2028–2030 if successful
Verve VERVE-104
Base-editor LPA gene therapy		 Future ~0 ~−10% −90% (target) Preclinical Single-dose IV — lifetime $$$ TBD ~2030+
Niacin · Bile-acid sequestrants · Red yeast rice Deprecated varies varies −25% (niacin) AIM-HIGH negative for niacin varies varies Generally superseded

Emerging Treatments — Deep Dive

The next 24–48 months will reshape the Lp(a) lever entirely. These are the five treatments worth tracking actively. Trial readouts feed your Lp(a) tracker page (updated monthly).
Pelacarsen Novartis (TQJ230) · Antisense oligonucleotide targeting LPA mRNA
Phase 3
Lp(a) Δ~−80%
RouteSubQ monthly
Readout~2027
HORIZON trial (n=8,323, established CV disease + Lp(a) ≥175 nmol/L). If positive, becomes the first approved Lp(a)-specific therapy. Relevance to you: your Lp(a) 90 nmol/L is below the trial inclusion floor; you'd be off-label initially.
Olpasiran Amgen (AMG 890) · siRNA against LPA
Phase 3
Lp(a) Δ~−94%
RouteSubQ q12 wks
Readout2027–2028
OCEAN(a)-Outcomes trial. siRNA mechanism gives ~94% Lp(a) reduction — the cleanest of any class. Q12-week dosing is the practical winner over Pelacarsen's monthly schedule. Likely highest probability of becoming the dominant Lp(a) drug.
Muvalaplin Eli Lilly (LY3473329) · Oral small-molecule Lp(a) inhibitor
Phase 2
Lp(a) Δ~−85%
RouteOral 1×/day
Readout2026–2027 (Ph2 KRAKEN)
First and only oral Lp(a)-lowering drug. Blocks apo(a)–apoB100 covalent assembly. Game-changer if approved: daily pill vs. injection means dramatically higher real-world adherence. Ph3 program will follow Ph2 readout.
Obicetrapib NewAmsterdam Pharma · CETP inhibitor
Phase 3
LDL Δ−50%
Lp(a) Δ−40 to −50%
RouteOral 1×/day
Resurrection of the CETP-inhibitor class (after prior failures: torcetrapib, dalcetrapib, anacetrapib). Positive BROADWAY/BROOKLYN Ph3 results 2025. Uniquely addresses BOTH your LDL AND Lp(a) in one oral pill. FDA filing expected 2026.
Verve VERVE-102 Verve Therapeutics · CRISPR base-editor PCSK9 gene therapy
Phase 1b
LDL Δ~−55%
RouteSingle IV infusion
StatusHeart-2 trial enrolling
One-time IV infusion → permanently edits PCSK9 in the liver → lifetime LDL reduction. If successful, fundamentally changes the calculus — "for life" becomes "one treatment, done." VERVE-104 targets LPA gene similarly (preclinical). 5–7 year horizon for approval.
Inclisiran Novartis (Leqvio) · siRNA PCSK9 · ALREADY APPROVED
Approved
LDL Δ−50%
RouteSubQ q6 months
CV outcomeORION-4 due 2026
Available now but typically reserved for post-statin/ezetimibe inadequate response. Twice-yearly injection is best-in-class adherence. Watch ORION-4 readout in 2026 — if hard CV outcome benefit confirmed, indication may broaden significantly.

Stacking Logic — What Composes, What Conflicts

✓ Compose — additive or synergistic

  • Statin + ezetimibe — canonical combo, additive ~25% extra LDL on top of statin (IMPROVE-IT)
  • Statin + PCSK9i — up to 75% total LDL reduction
  • Ezetimibe + bempedoic acid — well-tolerated all-oral alternative to statin
  • Psyllium + anything — different mechanism (bile-acid binding), genuinely additive
  • Lp(a) siRNA + LDL-lowerer — independent targets, fully additive
  • Obicetrapib + statin — Ph3 data shows additive on top of stable statin

✗ Conflict — duplicative or antagonistic

  • Ezetimibe + phytosterols — same NPC1L1 target. Ezetimibe wins, sterols become wasted dose. Drop sterols when starting ezetimibe.
  • Statin's Lp(a)-raising effect — statins increase Lp(a) ~10–30%. Concerning if Lp(a) already elevated (you). Mitigated by ezetimibe (Lp(a)-neutral) or PCSK9i (Lp(a)-lowering).
  • Niacin + statin — AIM-HIGH and HPS2-THRIVE negative; niacin essentially dead as add-on therapy
  • Multiple PCSK9-targeting agents — don't stack mAb + Inclisiran (redundant target)
  • Bile-acid sequestrants + ezetimibe — physical absorption interference; if combined, separate by ≥2 hrs

Decision Tree — "I'm On Psyllium, What's Next?"

✓

Step 0 — Established baseline (DONE / IN PROGRESS)

Psyllium 5–10 g/day · Mediterranean-style diet · Zone 2 + resistance training · sleep optimized.

Expected effect with full optimization: ApoB 108 → ~100–102 mg/dL. Still well above target. Lifestyle alone won't close your gap to ApoB <80.

Trigger to advance: ApoB still >90 at 12-week recheck after psyllium uptitration
1

Step 1 — Ezetimibe 10 mg/day (your next move)

Cleanest next pharmacological lever. Single oral pill, $10/mo generic, excellent safety. ApoB −15 to −20%, LDL-C −18 to −20%. Telehealth Rx is the fastest path; PCP is the proper path.

Why ezetimibe before statin: (1) Doesn't raise Lp(a) (your concern); (2) Safer than statin for muscle/cognitive; (3) Has CV outcome data (IMPROVE-IT). (4) Re-check labs at 12 weeks, then decide if you need more.

Expected: ApoB 108 → ~91 mg/dL. Still slightly above target.

Trigger to advance: ApoB still >80 at 12-week recheck on ezetimibe
2

Step 2 — Add low-dose statin OR bempedoic acid

Statin path: Rosuvastatin 5 mg or Atorvastatin 10 mg. Adds another 30–40% LDL reduction on top of ezetimibe. ApoB likely → ~65–70 mg/dL. Downside: ~10–20% Lp(a) increase; counteract with PCSK9i if Lp(a) becomes the issue.

Bempedoic acid path: Nexletol 180 mg. Adds ~17–25% LDL on top of ezetimibe. CV outcome data (CLEAR-Outcomes 2023). No Lp(a) raise, no muscle issues. Downside: $400/mo branded only; insurance may push you to statin first.

Expected: ApoB on target (<80, ideally <70).

Trigger to advance: very rare — only if ApoB still >70 with combo + adherence confirmed
3

Step 3 — PCSK9 inhibitor (unlikely needed for you)

Repatha, Praluent, or Inclisiran (Leqvio). Reserved for patients who can't get to target on Step 2, or who have established CV disease. For your CAC 0 / primary prevention profile, this is overkill barring unusual circumstances.

If you ever escalate here, the Lp(a)-lowering bonus (−20 to −30%) is a real side-benefit
L

Lp(a)-specific lever — parallel track, future

None of the steps above meaningfully lower your Lp(a) 90 nmol/L. The real Lp(a) lever is the siRNA class — Pelacarsen (FDA likely 2027), Olpasiran (likely 2028), Muvalaplin (oral, ~2028).

For now: track via Lp(a) tracker. When the first one lands and labeling permits Lp(a) 75+ nmol/L, that's the moment to add it on top of whatever LDL stack you're running.

Recommended 5-Year Sequence

Now (Q2 2026)
Psyllium 10 g/day BID (5 g AM shake + 5 g pre-dinner). Maintain diet and Zone 2 + resistance training. Decide on plant sterols (recommended: defer in favor of ezetimibe).
Q3 2026
Start ezetimibe 10 mg/day. Telehealth Rx or PCP. Re-test lipid panel + ApoB + Lp(a) + LFTs at 12 weeks.
Q1 2027
Review labs. If ApoB <80, hold. If >80, add rosuvastatin 5 mg OR bempedoic acid. Re-test 12 weeks.
2027
Pelacarsen Ph3 (HORIZON) readout expected. If positive, FDA filing initiates. Watch Lp(a) tracker.
2027–2028
Olpasiran Ph3 (OCEAN(a)) readout. Likely best-in-class siRNA. Muvalaplin Ph3 also progresses.
2028
First Lp(a)-specific drug likely available. If labelling permits Lp(a) 75+ nmol/L, add to stack. By this point you should be at ApoB target and adding a Lp(a)-specific tool finally addresses your dominant residual risk.
2029
Repeat CAC (5-year follow-up). Target: still 0, validating current stack. If progressed, intensify accordingly.
2030+
Verve gene editing (VERVE-102 PCSK9, VERVE-104 LPA) in late phase. If successful, potential to collapse the daily-pill burden into one-time treatments. Reassess strategy.
Built 27 May 2026 · Synthesized from existing AI Doctor evidence base + 2025 ESC/EAS Focused Update on dyslipidaemia + 2024 NLA expert consensus on ApoB targets + clinical-trials.gov Lp(a) pipeline status.
This is a decision view, not a prescription. Drug selection, dosing, monitoring, and contraindications are clinical decisions for your physician. This page exists to organize the landscape so you walk into that conversation prepared.
Cadence: Refresh on each lab reading, on Lp(a)-tracker pipeline updates, and at minimum quarterly. Auto-monitored via longevity-monthly-refresh scheduled task.